All Episodes
Community Health Media — 43 episodes
Dr. Megan Kruse & Dr. Lukas Delasos - ADC Integration & Toxicity in Breast and Thoracic Oncology
Dr. Rao & Dr. Nasrazadani – The Second-Line Landscape for HR+/HER2- mBC: The Role of Capivasertib
Dr. Hope Rugo & Dr. Rebecca Shatsky - Dato-DXd & First-Line ADC Strategies in Metastatic TNBC
Dr. Hope Rugo & Dr. Rebecca Shatsky - Earlier ESR1 Detection & Oral SERDs in Metastatic Breast Cancer
Dr. Neil Iyengar & Dr. Ticiana Leal - ADC Integration in Breast & Lung Cancer: The Role of Dato-DXd
Dr. Iyengar, Dr. Bhave & Dr. Mahtani – ESR1 Monitoring & Camizestrant in Metastatic Breast Cancer
Dr. Megan Kruse & Dr. Carol Tweed – ESR1 Mutation Monitoring & Oral SERDs in Metastatic Breast Cancer
Dr. Jason Mouabbi & Dr. Ahmed Elkhanany - SERENA-6, ESR1 Mutations & Molecular Progression
Dr. Rebecca Shatsky & Dr. Reva Basho - Sequencing PI3K/AKT Therapies in Metastatic Breast Cancer
Drs. Neil Iyengar, Manali Bhave & Reshma Mahtani - Navigating AKT Inhibition Efficacy & Tolerability
Dr. Erica Mayer & Dr. Seth Wander - Biomarker Testing & Precision Targeting in the PI3K Pathway
Dr. Seth Wander & Dr. Erica Mayer - SERENA-6 and Camizestrant in Breast Cancer
Drs. Alvarez, Dr. Mazo-Canola & Dr. Sandoval-Leon - The Future of Breast Cancer Treatment & Precision Oncology
Dr. Jason Mouabbi & Dr. Eric Singhi - ADCs in Breast & Lung Cancer
Dr. Sigrun Hallmeyer & Dr. William Gradishar - SERENA-6 & Early Endocrine Resistance
Dr. VK Gadi & Dr. Tarah Ballinger - DB09, PATINA, DB05 & DB11 in HER2+ Breast Cancer
Can T-DXd Change Early HER2+ Breast Cancer Forever? - Dr. Ruta Rao & Dr. VK Gadi
First-Line HER2+ Metastatic Breast Cancer: DESTINY-Breast09 & the Future of Care - Dr. Irene Kang & Dr. Aditya Bardia
Early-Stage HER2+ Breast Cancer: DESTINY-Breast11, DESTINY-Breast05 & What Comes Next - Dr. Neil Iyengar & Dr. Komal Jhaveri
Is HER2+ Metastatic Breast Cancer Curable? DESTINY-Breast09, Patina & What Comes Next - Dr. Gregory Vidal & Dr. Nusayba Bagegni
DB-11 & DB-05: Rewriting Neoadjuvant & Adjuvant HER2+ Breast Cancer Strategy - Dr. Alison Conlin & Dr. Heather McArthur
HER2+ Metastatic Breast Cancer: Cleopatra, DESTINY-Breast09 & What Comes Next - Drs. Bill Gradishar, Tarah Ballinger, & Megan Kruse
Is Cleopatra Finally Over? New First-Line Strategies in HER2+ Metastatic Breast Cancer - Dr. Mark Pegram & Dr. Carol Tweed
HER2+ Metastatic Breast Cancer: Is T-DXd + Pertuzumab the New First-Line Standard? - Drs. Neil Iyengar, Komal Jhaveri, & Igor Makhlin
DESTINY-Breast09: Has HER2+ First-Line Treatment Officially Changed? - Dr. Neil Iyengar & Dr. Martin Dietrich
HER2+ Metastatic Breast Cancer: Is DB09 Leading Towards A New First-Line Standard Of Care? - Drs. Amy Krie, Mabel Mardones, & Anne O'Dea
Destiny-Breast09: Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer? - Dr. Mark Pegram & Dr. Fengting Yan
Is First-Line mTNBC Changing? Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained - Dr. Bill Gradishar & Dr. Tiffany Traina
40-Month PFS? Rethinking First-Line Metastatic HER2+ Therapy with T-DXd - Drs. Mouabbi, O’Shaughnessy & Rimawi
ESMO 2025 Roundtable: Redefining HER2, ADCs & the Future of Breast Cancer Care
Dr. Neil Iyengar & Dr. Erika Hamilton - First-Line TNBC: How TRO-Breast02 & ASCENT-03 Change the Game
Dr. Gregory Vidal and Dr. Erika Hamilton - TDXd in Early Breast Cancer: What DB-05 & DB-11 Mean for Patients
Dr. Mark Pegram & Dr. Ana Garrido-Castro – Breakthrough Data in Metastatic TNBC
Dr. Jason Mouabbi, Dr. Irene Kang, and Dr. Ruemu Birhiray - HER2+ Early Breast Cancer: Beyond pCR and Toward Brain Protection
Dr. Neil Iyengar & Dr. Mark Robson - PARP Inhibitors in Early Breast Cancer: Who and When to Treat
Dr. Mark Pegram & Dr. Neil Iyengar - Beyond CLEOPATRA: T-DXd’s Rise in HER2+ and HER2-Low Breast Cancer
Dr. VK Gadi & Dr. Anne O'Dea - Advances in HER2 Positive Breast Cancer Treatment
Dr. VK Gadi & Dr. Jason Mouabbi - HER2 Positive & HER2 Low Updates and Therapies
Dr. Jason Mouabbi & Dr. Mothaffar Rimawi - DB09 & The Future of HER2+Care
Dr. Jason Mouabbi & Dr. Michelina Cairo - Talking DB04 and DB06
Dr. VK Gadi & Dr. Fengting Yan - Navigating HER2 Low and Ultra Low Disease
Dr. Aditya Bardia and Dr. Reena Callahan - Redefining HER2 Classifications and Treatments
Dr. Jason Mouabbi & Dr. Paolo Tarantino - T-Dxd, HER2 Low & The Future of Breast Cancer Treatment